BioWorld MedTech

Jan. 28, 2010

Prostate cancer treatments vary at county vs. private hospitals

Researchers at Moores Cancer Center at the University of California, San Diego (UCSD) and colleagues have found that prostate cancer treatments varied significantly between county hospitals and private providers. (Medical Device Daily) Read More

Halt's fibroid device, procedure to make other treatments 'irrelevant'

International report: Varian Medical certified to assemble X-ray tubes in China

BrandWatch develops marker to spot counterfeit devices

Washington roundup: Prior FDA move on drug tests opposed by Congress and DEA

Today's MDD food for med-tech thought

Financings roundup: HeartWare seeks to raise $50M in public offering of 1.5M shares

Agreements/contracts: Opsens' sensor tech integrated with Abiomed's heart pump

Patent watch: Neurologix gains protection for Parkinson's disease tech

Deals roundup: Imagine Media signs non-binding letter of intent to acquire DMI

Grants roundup: GE gets $3.27M to bring medical imaging to undeveloped countries

Med-Tech Notes

Product Briefs

MDD's Ortho Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...